|1.||Hunakova, L: 2 articles (01/2009 - 01/2005)|
|2.||Sedlak, J: 2 articles (01/2009 - 01/2005)|
|3.||Chovancova, J: 2 articles (01/2009 - 01/2005)|
|4.||Bodo, J: 2 articles (01/2009 - 01/2005)|
|5.||Jakubikova, J: 1 article (01/2009)|
|6.||Duraj, J: 1 article (01/2009)|
|7.||Liskova, Aurelia: 1 article (11/2002)|
|8.||Horvathova, Mira: 1 article (11/2002)|
|9.||Tulinska, Jana: 1 article (11/2002)|
|10.||Horakova, Katarina: 1 article (11/2002)|
01/01/2005 - "We conclude that E-4IB may be worth of further studies assessing its value in the ovarian carcinoma treatment, in combination with the other chemotherapeutic agents."
01/01/2005 - "Evaluation of the growth inhibitory effects of E-4IB in the human ovarian carcinoma cell line A2780 and its cisplatin-resistant variant A2780/CP using MTT-test and its apoptosis-inducing properties by flow cytometry was performed. "
01/01/2009 - "The aim of this study was to compare the effect of a new synthetic isothiocyanate derivative, ethyl 4-isothiocyanatobutanoate (E-4IB) and cisplatin (CDDP) in CDDP-sensitive human ovarian carcinoma cell line (A2780) and its resistant subline (A2780/CP). "
01/01/2005 - "Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate."
|2.||Sarcoma (Soft Tissue Sarcoma)
|5.||Body Weight (Weight, Body)